Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial.

ABSTRACT:

Objective

The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that glycemic failure rates were significantly lower in youth randomized to metformin plus rosiglitazone treatment than in youth randomized to metformin alone or metformin plus intensive lifestyle intervention. At the end of the study, rosiglitazone was permanently discontinued, and routine diabetes care resumed. Herein, we report postintervention glycemic failure rates in TODAY participants over an additional 36 months of follow-up for the three original treatment arms and describe insulin sensitivity and β-cell function outcomes.

Research design and methods

A total of 699 participants were randomized during TODAY, of whom 572 enrolled in the TODAY2 observational follow-u

SUBMITTER: TODAY Study Group 

PROVIDER: S-EPMC7783942 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature